Indeed, the sGC stimulator vericiguat has recently been reported to be effective in the clinical context of heart failure, reducing the rise of the combination of cardiovascular death and hospital admission for heart failure with no significant increase in associated major bleeding risk [32]. Here, SGCB is linked to heart failure.